Vacuolar proton-translocating ATPase is required for antifungal resistance and virulence of *Candida glabrata*

Asuka Minematsu\(^1,2\), Taiga Miyazaki\(^1,2\)*, Shintaro Shimamura\(^2\), Hiroshi Nishikawa\(^2\), Hironobu Nakayama\(^3\), Takahiro Takazono\(^1,2\), Tomomi Saijo\(^5\), Kazuko Yamamoto\(^2\), Yoshifumi Imamura\(^2\), Katsunori Yanagihara\(^4\), Shigeru Kohno\(^2\), Hiroshi Mukae\(^2\), Koichi Izumikawa\(^1\)

\(^1\) Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, \(^2\) Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan, \(^3\) Faculty of Pharmaceutical Sciences, Suzuka University of Medical Sciences, Mie, Japan, \(^4\) Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

\(^*\) taiga-m@nagasaki-u.ac.jp

Abstract

Vacuolar proton-translocating ATPase (V-ATPase) is located in fungal vacuolar membranes. It is involved in multiple cellular processes, including the maintenance of intracellular ion homeostasis by maintaining acidic pH within the cell. The importance of V-ATPase in virulence has been demonstrated in several pathogenic fungi, including *Candida albicans*. However, it remains to be determined in the clinically important fungal pathogen *Candida glabrata*. Increasing multidrug resistance of *C. glabrata* is becoming a critical issue in the clinical setting. In the current study, we demonstrated that the plecomacrolide V-ATPase inhibitor bafilomycin B\(_1\) exerts a synergistic effect with azole antifungal agents, including fluconazole and voriconazole, against a *C. glabrata* wild-type strain. Furthermore, the deletion of the *VPH2* gene encoding an assembly factor of V-ATPase was sufficient to interfere with V-ATPase function in *C. glabrata*, resulting in impaired pH homeostasis in the vacuole and increased sensitivity to a variety of environmental stresses, such as alkaline conditions (pH 7.4), ion stress (Na\(^+\), Ca\(^{2+}\), Mn\(^{2+}\), and Zn\(^{2+}\) stress), exposure to the calcineurin inhibitor FK506 and antifungal agents (azoles and amphotericin B), and iron limitation. In addition, virulence of *C. glabrata*Δvph2 mutant in a mouse model of disseminated candidiasis was reduced in comparison with that of the wild-type and *VPH2*-reconstituted strains. These findings support the notion that V-ATPase is a potential attractive target for the development of effective antifungal strategies.

Introduction

Invasive candidiasis is one of the most frequent fungal infections among a wide spectrum of immunocompromised patients, with the in-hospital mortality rates reported to be as high as 20–40% even among patients who receive antifungal therapy [1]. The therapeutic options...
Currently available to treat invasive candidiasis are limited to only four classes of antifungal agents: azoles, echinocandins, polyenes, and fluoropyrimidines. Further, the incidence rates of candidemia caused by non-\textit{albicans} \textit{Candida} species are increasing and antifungal resistance of these species has emerged as a serious problem in clinical practice [1–3]. The rise of multidrug resistance with unfavorable therapeutic outcome among \textit{Candida glabrata} infections became a critical healthcare issue in the last decade [4–6]. Therefore, the development of novel antifungal strategies is urgently needed.

Recent studies highlight vacuolar proton-translocating ATPase (V-ATPase) as an attractive target for drug discovery (reviewed in [7]). V-ATPase is an ATP-driven proton pump present in the endomembranes of all eukaryotic organisms [8, 9]. In particular, this proton pump is present in fungal vacuolar membranes, where it plays an important role in the maintenance of intracellular ion homeostasis by maintaining acidic pH within cell [10–12]. The V-ATPase is composed of 14 subunits that form two domains, a membrane-integral \textit{V}_0 domain and a cytoplasmic \textit{V}_1 domain; and assembly factors, including Vph2 (Vma12), Vma21, Vma22, and Pkr1, are required for the assembly of a functional yeast V-ATPase [9, 13–15]. In \textit{Saccharomyces cerevisiae}, V-ATPase synthesis and assembly are lost upon deletion of \textit{VPH2}, leading to changes in ion sensitivity, including calcium sensitivity [16]. Previously, we demonstrated that V-ATPase also plays an important role in endogenous and exogenous oxidative stress response by regulating the expression and activity levels of the superoxide dismutase Sod2 and catalase Cta1, respectively, in \textit{C. glabrata} [17].

Previous studies with mutant strains of \textit{Histoplasma capsulatum}, \textit{Cryptococcus neoformans}, and \textit{C. albicans} lacking specific subunits of V-ATPase demonstrated that loss of V-ATPase function leads to vacuolar alkalinization and attenuation of \textit{in vivo} virulence [18–21]. However, the link between V-ATPase function and virulence in \textit{C. glabrata} has not been reported. In the current study, we investigated the effects of V-ATPase defect in \textit{C. glabrata} on responses to various environmental stresses, antifungal resistance, and virulence.

**Materials and methods**

**Strains, culture conditions, and compounds**

\textit{C. glabrata} strain CBS138 [22] was used as a wild-type control. \textit{C. glabrata Δvph2} deletion mutant lacking the entire \textit{VPH2} open reading frame (NCBI accession no.: XP_448720, \textit{Candida} genome database ID: CAGL0K11594g) and a \textit{VPH2}-reconstituted strain, in which an intact \textit{VPH2} was reintroduced at the native locus in the genome of the \textit{Δvph2} mutant, were constructed previously [17]. \textit{C. glabrata} cells were propagated in yeast peptone dextrose (YPD) medium [1% (wt/vol) yeast extract, 2% (wt/vol) peptone, and 2% (wt/vol) glucose] or synthetic complete medium (SC) [0.67% (wt/vol) yeast nitrogen base with amino acids and 2% (wt/vol) glucose] at 30°C, unless otherwise specified. Media were solidified by the addition of 1.5% (wt/vol) agar. Fluconazole, voriconazole, amphotericin B, and FK506 were purchased from Sigma-Aldrich (St. Louis, MO). Bafilomycin B\textsubscript{1} was purchased from Santa Cruz Biotechnology (Dallas, TX). Desferrioxamine (DFO) was purchased from EMD Chemicals (San Diego, CA) and bathophenanthroline disulfonate (BPS) was from MP Biomedicals (SOLON, OH). Voriconazole, bafilomycin B\textsubscript{1}, and FK506 were dissolved in dimethyl sulfoxide and other compounds were dissolved in distilled water. Cell growth was not affected by exposure to the quantities of dimethyl sulfoxide used in the current study.

**Drug susceptibility assays**

Susceptibility to fluconazole, voriconazole, and the V-ATPase inhibitor bafilomycin B\textsubscript{1}, alone or in combination, was examined by using broth microdilution test, essentially according to
the Clinical and Laboratory Standards Institute (CLSI) M27-S4 protocol [23] and the previous report [24] with minor modifications. Briefly, *C. glabrata* cells were incubated in SC at 35˚C for 48 h. The minimum drug concentration that inhibited cell growth by more than 80% relative to drug-free control was defined as the minimum inhibitory concentration (MIC). Fractional inhibitory concentration (FIC) was calculated by using the following formula: FIC for drug A = (MIC of drug A in combination with drug B)/(MIC of drug A alone). The sum of FIC for drug A and FIC for drug B was defined as the FIC index (FICI). Drug interaction was classified as synergistic if FICI was ≤0.5 [25].

Spot dilution test was performed as described previously [26]. Briefly, the density of logarithmic-phase cultures in SC was adjusted to the concentration of 2 × 10^7 cells/ml. Serial 10-fold dilutions in SC were then prepared, and 5 μl of each dilution was spotted onto SC plates containing the test compound at the desired concentrations. Plates were incubated at 30˚C for 48 h and photographed.

All sensitivity tests were performed on at least three separate occasions to ensure reproducibility.

**Staining of fungal cells**

Vacuolar staining with the styryl dye N-(3-triethylammoniumpropyl)-4-(6-(4-(diethylamino)phenyl)hexatrienyl)pyridinium dibromide (FM4-64; Thermo Fisher Scientific, Molecular Probes, Eugene, OR) and the pH-sensitive fluorophore 2N,7N-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM; Thermo Fisher Scientific, Molecular Probes) was performed as described previously [27, 28] with few modifications. Briefly, logarithmic-phase cells of *C. glabrata* were washed and resuspended in SC broth (pH 5.0). FM4-64 was added to cell suspensions (final concentration: 5 μM) and the mixtures were incubated at 30˚C for 15 min to stain vacuole membranes. Cells were washed in SC with agitation for 90 min and resuspended in SC. BCECF-AM was added to cell suspensions (final concentration: 18 μM) and incubated at 30˚C for 60 min. Cells were washed twice in SC, and microscopic examination was performed immediately after washing. Images were acquired using a Carl Zeiss LSM780 confocal laser-scanning microscope and processed using ZEN 2011 software (Carl Zeiss, Jena, Germany). The excitation and emission parameters were as follows: 560 and 605 nm, respectively, for FM4-64; and 470 and 535 nm, respectively, for BCECF-AM.

**Virulence assay**

Specific pathogen–free 8-week-old female BALB/c mice, weighing approximately 20 g, were purchased from Charles River Laboratories Japan (Yokohama, Japan). All mice had free access to food and water and were housed in a light–and temperature–controlled room at the Biomedical Research Center, Life Science Support Center, Nagasaki University. The health status of all mice was monitored at least daily throughout the experiments. All animal experiments were performed in full compliance with the Guide for the Care and Use of Laboratory Animals [29] and all institutional regulations and guidelines for animal experimentation, after pertinent review and approval by the Institutional Animal Care and Use Committee of Nagasaki University (protocol number 1407281164).

Logarithmic-phase cells of *C. glabrata* wild-type, Δvph2, and VPH2-reconstituted strains were harvested, washed, and resuspended in sterile saline, and cell density was adjusted to 4 × 10^8 cells/ml. The actual colony forming units (CFUs) used were confirmed by plating serial dilutions of the cell suspensions on YPD plates and incubating at 30˚C overnight. Mice (n = 7 for wild-type, n = 9 for Δvph2, and n = 8 for Δvph2 + VPH2, per experiment) were inoculated with 0.2 ml of each cell suspension via the lateral tail vein. Mice were euthanized by carbon
Results

Synergistic effects of azoles and the V-ATPase inhibitor bafilomycin B₁ against *C. glabrata*

Azole antifungals, including fluconazole and voriconazole, inhibit the biosynthesis of ergosterol, the major component of fungal cell membrane, by targeting lanosterol 14α-demethylase encoded by *ERG11* [30]. V-ATPase is pharmacologically inhibited by the plecomacrolide bafilomycin B₁, which binds to the V0 subunit of V-ATPase, and simultaneously interferes with ATP hydrolysis and proton transport [31, 32]. To examine the effect of bafilomycin B₁ on azole susceptibility of *C. glabrata* wild-type strain, we performed a checkerboard assay using serial 2-fold dilutions of the drugs. In the assay, MICs of fluconazole, voriconazole, and bafilomycin B₁ were determined to be >64, 4, and >32 μg/ml, respectively (Fig 1). FIC indices of the combination of fluconazole and bafilomycin B₁, and the combination of voriconazole and bafilomycin B₁ were 0.375 and 0.313, respectively, indicating synergistic effects of these azoles and bafilomycin B₁ against *C. glabrata*.

Deletion of the V-ATPase assembly factor gene *VPH2* leads to impaired vacuole acidification in *C. glabrata*

To investigate the role of V-ATPase in *C. glabrata* in detail, we analyzed the phenotype of the Δvph2 mutant, by comparing it with that of the wild-type and VPH2-reconstituted strains. First, *C. glabrata* cells were incubated with FM4-64, which selectively stains yeast vacuolar membranes and may be detected by red fluorescence [33, 34]. The wild-type and VPH2-reconstituted strains exhibited the typical ring-staining pattern of the vacuole membrane, while FM4-64 accumulated within the vacuole lumen in the Δvph2 mutant (Fig 2). The impaired trafficking of FM4-64 to the vacuolar membrane in the Δvph2 mutant was consistent with...
endocytosis defects demonstrated by *C. albicans* vma mutants [21] and *C. albicans* cells treated with fluconazole [28].

The cells were then labeled with the pH-sensitive fluorescent dye BCECF-AM. The dye labeled the vacuoles of the Δvph2 mutant but not those of the wild-type and VPH2-reconstituted strains (Fig 2). This indicated impaired vacuolar acidification in the Δvph2 mutant, as would be expected after loss of proton pump capacity.

**Loss of Vph2 results in increased fungal sensitivity to various environmental stresses**

The phenotype of the Δvph2 mutant was further examined by spot dilution assays. In agreement with the notion of impaired vacuole acidification even under acidic conditions (Fig 2), the Δvph2 mutant exhibited a growth defect at pH 5.0 and was unable to grow at pH 7.4 (Fig 3). The Δvph2 mutant also displayed increased sensitivity to ion stress induced by excess of NaCl, CaCl₂, MnCl₂, and ZnCl₂ in the growth medium.

The Ca²⁺/calmodulin-dependent protein phosphatase calcineurin plays a critical role in maintaining intracellular ion homeostasis and cell integrity. Further, simultaneous loss of certain subunits of V-ATPase and calcineurin is synthetically lethal in *S. cerevisiae* [35, 36]. In agreement with the findings for *S. cerevisiae*, the *C. glabrata* Δvph2 mutant was unable to grow in the presence of the calcineurin inhibitor FK506 (Fig 3). In addition to fluconazole and voriconazole, the Δvph2 mutant displayed increased susceptibility to fenpropimorph, which inhibits C-8 sterol isomerase (Erg2) and C-14 sterol reductase (Erg24) in the ergosterol biosynthesis pathway.
pathway [37, 38], and amphotericin B, which directly targets ergosterol [39]. Finally, the Δvph2 mutant also exhibited growth defects under iron-limited conditions induced by the inclusion of the bacterial siderophore DFO or the Fe^{2+}-chelator BPS in the growth medium.

**Loss of Vph2 results in reduced fungal virulence in a murine model of disseminated candidiasis**

The effect of VHP2 deletion on the virulence of *C. glabrata* was examined using a mouse model of disseminated candidiasis. No mice died prior to euthanasia in the experiments. Fungal burdens in the examined organs of immunocompetent mice infected with the Δvph2 mutant were significantly lower than those in mice infected with the wild-type or VPH2-reconstituted strains (Fig 4). This suggested that V-ATPase plays an important role in the virulence in *C. glabrata*.

**Discussion**

Overcoming the antifungal resistance of *C. glabrata* in the clinical setting is a pressing issue. In the current study, we demonstrated the synergistic effect of the V-ATPase inhibitor bafilomycin B1 andazole antifungals against a *C. glabrata* wild-type strain. Azole antifungals exert an antifungal effect partly by impairing vacuolar acidification, since ergosterol is required for V-ATPase to function efficiently [28]. The concurrent disruption of ergosterol and V-ATPase was induced by exposing the Δvph2 mutant to ergosterol inhibitors, leading to the severe growth impairment of the Δvph2 mutant (Fig 3). Some *C. glabrata* Δvph2 phenotypes were anticipated based on the published findings in *S. cerevisiae* and *C. albicans*. However, in the current study, we demonstrated for the first time that the loss of Vph2 in *C. glabrata* results in a V-ATPase defect, which leads to impaired vacuolar pH homeostasis and increased sensitivity to a variety of environmental stresses, as well as attenuated virulence in mice. The growth defect of the Δvph2 mutant could contribute to the enhanced susceptibility to diverse drugs tested and decreased virulence.

The Δvph2 mutant was unable to grow under iron-limiting conditions. Requirement of V-ATPase for iron homeostasis was also demonstrated in *H. capsulatum* [19]. Iron acquisition and iron homeostasis are important virulence factors in pathogenic fungi. For example, *C. albicans* must obtain hemoglobin iron to survive under the iron-limiting conditions in host tissues, and functional V-ATPase is required for iron acquisition in the microorganism [40].
Targeting a conserved protein that plays an essential role in human and fungal cells is challenging as it entails averting host toxicity. For instance, V-ATPase is present in the renal tubules and osteoclasts in mammals, including human [8]. However, although V-ATPase is highly conserved in eukaryotes, some major differences between mammalian and fungal V-ATPases exist, particularly with respect to the isoform composition of subunits and in the regulation of complex disassembly [41–45]. The different numbers and types of isoforms have been developed for most subunits of the mammalian V-ATPase [7]. The sequence conservation between S. cerevisiae and human V-ATPase subunits is 51–60% similarity and 31–41% identity, depending on the subunit and isoform [44]. C. glabrata VPH2 encodes a putative protein of 209 amino acids, with a molecular mass of 23.4 kDa. The deduced amino acid sequences of C. glabrata VPH2 share 61.8% similarity and 41.9% identity with those of S. cerevisiae VPH2 (NCBI Gene ID 853741, NCBI accession no. CAA81960), but only 32.6% similarity and 18.1% identity with those of a human homolog (TMEM199: NCBI Gene ID 147007, NCBI accession no. NP_689677) (S1 Fig). These different features could potentially be exploited to selectively target V-ATPase of pathogenic fungi.

In conclusion, in the current study, we provided evidence that disruption of C. glabrata V-ATPase function by deleting VPH2 impairs the fungal response to various environmental stresses and results in the attenuation of virulence of this clinically important fungal pathogen, supporting the notion that V-ATPase is an attractive antifungal target.

Supporting information
S1 Fig. Sequence alignment of the deduced amino acids of C. glabrata VPH2 with those of S. cerevisiae VPH2 and a human homolog TMEM199. Identical and similar amino acids are
shown as darkly shaded and lightly shaded regions, respectively. GenBank accession number: *C. glabrata* VPH2, XP_448720; *S. cerevisiae* VPH2, CAA81960; and TMEM199, NP_689677.

**Author Contributions**

**Conceptualization:** Taiga Miyazaki.

**Data curation:** Asuka Minematsu, Shintaro Shimamura, Hiroshi Nishikawa, Hironobu Nakayama.

**Formal analysis:** Asuka Minematsu.

**Funding acquisition:** Taiga Miyazaki, Shigeru Kohno, Hiroshi Mukae, Koichi Izumikawa.

**Investigation:** Asuka Minematsu.

**Methodology:** Asuka Minematsu, Taiga Miyazaki, Shintaro Shimamura, Hiroshi Nishikawa, Hironobu Nakayama, Takahiro Takazono, Tomomi Saijo, Kazuko Yamamoto, Yoshifumi Imamura, Katsunori Yanagihara.

**Project administration:** Taiga Miyazaki.

**Supervision:** Taiga Miyazaki, Shigeru Kohno, Hiroshi Mukae, Koichi Izumikawa.

**Validation:** Asuka Minematsu, Taiga Miyazaki, Hiroshi Nishikawa.

**Visualization:** Asuka Minematsu.

**Writing – original draft:** Asuka Minematsu, Taiga Miyazaki.

**Writing – review & editing:** Taiga Miyazaki, Hiroshi Mukae, Koichi Izumikawa.

**References**

1. Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015; 373(15):1445–1456. https://doi.org/10.1056/NEJMra1315399 PMID: 26444791

2. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in *Candida albicans* and emerging non-*albicans Candida* species. Front Microbiol. 2017; 7:2173. https://doi.org/10.3389/fmicb.2016.02173 PMID: 28127295

3. Wiederhold NP. Antifungal resistance: current trends and future strategies to combat. Infect Drug Resist. 2017; 10:249–259. https://doi.org/10.2147/IDR.S124918 PMID: 28919789

4. Arendrup MC, Patterson TF. Multidrug-resistant *Candida*: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017; 216(Suppl 3):S445–S451. https://doi.org/10.1093/infdis/jix131 PMID: 28911043

5. Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017; 17(12):e383–e392. https://doi.org/10.1016/S1473-3099(17)30316-X PMID: 28774698

6. Pfalter MA, Castanheira M, Lockhart SR, Ahiquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of *Candida glabrata*. J Clin Microbiol. 2012; 50(4):1189–1203. https://doi.org/10.1128/JCM.06112-11 PMID: 22278842

7. Hayek SR, Lee SA, Parra KJ. Advances in targeting the vacuolar proton-translocating ATPase (V-ATPase) for anti-fungal therapy. Front Pharmacol. 2014; 5:4. https://doi.org/10.3389/fphar.2014.00004 PMID: 24478704

8. Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol. 2007; 8(11):917–929. https://doi.org/10.1038/nrm2272 PMID: 17912264

9. Kane PM. The where, when, and how of organelle acidification by the yeast vacuolar H+-ATPase. Microbiol Mol Biol Rev. 2006; 70(1):177–191. https://doi.org/10.1128/MMBR.70.1.177-191.2006 PMID: 16524922
10. Bond S, Forgac M. The Ras/cAMP/protein kinase A pathway regulates glucose-dependent assembly of the vacuolar (H+)-ATPase in yeast. J Biol Chem. 2008; 283(52):36513–36521. https://doi.org/10.1074/jbc.M805232200 PMID: 18936098

11. Graham LA, Stevens TH. Assembly of the yeast vacuolar proton-translocating ATPase. J Bioenerg Bioembr. 1999; 31(1):39–47. PMID: 10340847

12. Huss M, Vitavska O, Albertmelcher A, Bockelmann S, Nardmann C, Tabke K, et al. Vacuolar H (+)-ATPases: intra- and intermolecular interactions. Eur J Cell Biol. 2011; 90(9):688–695. https://doi.org/10.1016/ j.ejcb.2011.04.009 PMID: 21640428

13. Davis-Kaplan SR, Compton MA, Flannery AR, Ward DM, Kaplan J, Stevens TH, et al. PKR1 encodes an assembly factor for the yeast V-type ATPase. J Biol Chem. 2006; 281(42):32025–32035. https://doi.org/10.1074/jbc.M606451200 PMID: 16926153

14. Graham LA, Hill KJ, Stevens TH. Assembly of the yeast vacuolar H+-ATPase occurs in the endoplasmic reticulum and requires a Vma12p/Vma22p assembly complex. J Cell Biol. 1998; 142(1):39–49. PMID: 9660861

15. Kane PM, Stevens TH. The long physiological reach of the yeast vacuolar H+-ATPase. J Bioenerg Bioembr. 2007; 39(5–6):415–421. https://doi.org/10.1007/s10863-007-9112-z PMID: 18000744

16. Hirata R, Umemoto N, Ho MN, Ohya Y, Stevens TH, Anraku Y. VMA12 is essential for assembly of the vacuolar H(+)-ATPase subunits onto the vacuolar membrane in Saccharomyces cerevisiae. J Biol Chem. 1993; 268(2):961–967. PMID: 8419376

17. Nishikawa H, Miyazaki T, Nakayama H, Minematsu A, Yamauchi S, Yamashita K, et al. Roles of vacuolar H+-ATPase in the oxidative stress response of Candida glabrata. FEMS Yeast Res. 2016; 16(5). pii: fow054. https://doi.org/10.1093/femsyr/fow054 PMID: 27370212

18. Erickson T, Liu L, Gueyikian A, Zhu X, Gibbons J, Williamson PR. Multiple virulence factors of Cryptococcus neoformans are dependent on VPH1. Mol Microbiol. 2001; 42(4):1121–1131. PMID: 11737651

19. Hilty J, Smulian AG, Newman SL. The Histoplasma capsulatum vacuolar ATPase is required for iron homeostasis, intracellular replication in macrophages and virulence in a murine model of histoplasmosis. Mol Microbiol. 2008; 70(1):127–139. https://doi.org/10.1111/j.1365-2958.2008.06395.x PMID: 1869866

20. Patenaude C, Zhang Y, Cormack B, Köhler J, Rao R. Essential role for vacuolar acidification in Candida albicans virulence. J Biol Chem. 2013; 288(36):26256–26264. https://doi.org/10.1074/jbc.M113.494815 PMID: 23884420

21. Poltermann S, Nguyen M, Günther J, Wendland J, Härtl A, Künkel W, et al. The putative vacuolar ATPase subunit Vma7p of Candida albicans is involved in vacuole acidification, hyphal development and virulence. Microbiology. 2005; 151(Pt 5):1645–1655. https://doi.org/10.1099/mic.0.27505-0 PMID: 15870472

22. Dujon B, Sherman D, Fischer G, Durrens P, Casaregola S, Lafontaine I, et al. Genome evolution in yeasts. Nature. 2004; 430(6995):35–44. https://doi.org/10.1038/nature02579 PMID: 15229592

23. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. CLSI document M27-S4. Wayne, PA.: Clinical and Laboratory Standards Institute; 2012.

24. Nagayoshi Y, Miyazaki T, Shimamura S, Nakayama H, Minematsu A, Yamauchi S, et al. Unexpected effects ofazole transporter inhibitors on antifungal susceptibility in Candida glabrata and other pathogenic Candida species. PLoS One. 2017; 12(7):e0180990. https://doi.org/10.1371/journal.pone.0180990 PMID: 2870066

25. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother. 2004; 48(3):693–715. https://doi.org/10.1128/AAC.48.3.693-715.2004 PMID: 14982754

26. Miyazaki T, Nakayama H, Nagayoshi Y, Kakeya H, Kohno S. Dissection of Ire1 functions reveals stress response mechanisms uniquely evolved in Candida glabrata. PLoS Pathog. 2013; 9(1):e1003160. https://doi.org/10.1371/journal.ppat.1003160 PMID: 23382685

27. Johnson RM, Allen C, Melman SD, Waller A, Young SM, Sklar LA, et al. Identification of inhibitors of vacuolar proton-translocating ATPase pumps in yeast by high-throughput screening flow cytometry. Anal Biochem. 2010; 398(2):203–211. https://doi.org/10.1016/j.ab.2009.12.020 PMID: 20018164

28. Zhang YY, Gamarra S, Garcia-Effron G, Park S, Perlin DS, Rao R. Requirement for ergosterol in V-ATPase function underlies antifungal activity ofazole drugs. PLoS Pathog. 2010; 6(6):e1000939. https://doi.org/10.1371/journal.ppat.1000939 PMID: 20532216

29. Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Guide for the care and use of laboratory animals. Washington DC: National Academy Press; 2011.
30. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol. 2003; 11(6):272–279. PMID: 12823944
31. Bowman EJ, Siebers A, Altendorf K. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci U S A. 1988; 85(21):7972–7976. PMID: 2973058
32. Drose S, Bindsei KU, Bowman EJ, Siebers A, Zeeck A, Altendorf K. Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases. Biochemistry. 1993; 32(15):3902–3906. PMID: 8385991
33. Bairwa G, Rasheed M, Taigwal R, Sahoo R, Kaur R. GPI (glycosylphosphatidylinositol)-linked aspartyl proteases regulate vacuole homeoestasis in Candida glabrata. Biochem J. 2014; 458(2):323–334. https://doi.org/10.1042/BJ20130757 PMID: 24341558
34. Vida TA, Emr SD. A new vital stain for visualizing vacuolar membrane dynamics and endocytosis in yeast. J Cell Biol. 1995; 128(5):779–92. PMID: 7533169
35. Garrett-Engele P, Molianen B, Cyert MS. Calcineurin, the Ca2+/calmodulin-dependent protein phosphatase, is essential in yeast mutants with cell integrity defects and in mutants that lack a functional vacuolar H(+)-ATPase. Mol Cell Biol. 1995; 15(8):4103–4114. PMID: 7542741
36. Hemenway CS, Dolinski K, Cardenas ME, Hiller MA, Heitman J. vph6 mutants of Saccharomyces cerevisiae require calcineurin for growth and are defective in vacuolar H(+)-ATPase assembly. Genetics. 1995; 141(3):833–844. PMID: 8582630
37. Jia N, Arthington-Skaggs B, Lee W, Pierson CA, Lees ND, Eckstein J, et al. Candida albicans sterol C-14 reductase, encoded by the ERG24 gene, as a potential antifungal target site. Antimicrob Agents Chemother. 2002; 46(4):947–957. https://doi.org/10.1128/AAC.46.4.947-957.2002 PMID: 11897574
38. Marcireau C, Guilloton M, Karst F. In vivo effects of fenpropimorph on the yeast Saccharomyces cerevisiae and determination of the molecular basis of the antifungal property. Antimicrob Agents Chemother. 1990; 34(6):989–993. PMID: 2203312
39. Gray KC, Palacios DS, Dailey I, Endo MM, Uno BE, Wilcock BC, et al. Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci U S A. 2012; 109(7):2234–2239. https://doi.org/10.1073/pnas.1117280109 PMID: 22308411
40. Weissman Z, Shemer R, Conibear E, Komitzer D. An endocytic mechanism for haemoglobin-iron acquisition in Candida albicans. Mol Microbiol. 2008; 69(1):201–217. https://doi.org/10.1111/j.1365-2958.2008.06277.x PMID: 18466294
41. Finnigan GC, Hanson-Smith V, Stevens TH, Thornton JW. Evolution of increased complexity in a molecular machine. Nature. 2012; 481(7381):360–364. https://doi.org/10.1038/nature10724 PMID: 22230956
42. Jefferies KC, Cipriano DJ, Forgac M. Function, structure and regulation of the vacuolar (H+)−ATPases. Arch Biochem Biophys. 2008; 476(1):33–42. https://doi.org/10.1016/j.abb.2008.03.025 PMID: 18406336
43. Kane PM. Targeting reversible disassembly as a mechanism of controlling V-ATPase activity. Curr Protein Pept Sci. 2012; 13(2):117–123. PMID: 22044153
44. Rahman S, Yamato I, Saijo S, Mizutani K, Ishizuka-Katsura Y, Ohsawa N, et al. Biochemical and biophysical properties of interactions between subunits of the peripheral stalk region of human V-ATPase. PLoS One. 2013; 8(2):e55704. https://doi.org/10.1371/journal.pone.0055704 PMID: 23409023
45. Toei M, Saum R, Forgac M. Regulation and isoform function of the V-ATPases. Biochemistry. 2010; 49(23):4715–4723. https://doi.org/10.1021/bi100397s PMID: 20450191